OROS-Methylphenidate
ApprovedSmall molecule
OROS-Methylphenidate is one of 79 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Approved.
3
Indications
13
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
169 competitors in Memory
#DrugCompanyPhaseTrials
1Lexapro
AbbViePhase 3
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Pneumococcal Vaccine
GSKPhase 3
Bupropion XL
GSKPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Atgam
NovartisPhase 2
Cysteine Hydrochloride
NovartisPhase 2
Nicorette
PfizerPhase 2
OROS-Methylphenidate
JJohnson & Johnson Taiwan Ltd
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Attention Deficit Hyperactivity Disorder4 trials
Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)
Completed·—·Phase 4·NCT00842127·150 enrolled
Adolescent1 trial
Medication1 trial
The Effects of ADHD Medication (TEAM) Study
Completed·—·Phase 4·NCT02293655·204 enrolled
4 more indications
Attention1 trial
Aggressive Behavior1 trial
Memory1 trial
Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
Completed·—·Phase 4·NCT00530257·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OROS-Methylphenidate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJohnson & Johnson Taiwan Ltd